In July 2023, The Department of Health and Social Care (DHSC) published a consultation on the design of the Statutory Scheme for Branded Medicines Pricing and Access (“the statutory scheme”) from 2024 onwards.
NERA Economic Consulting was commissioned by the ABPI to examine the economic reasoning and analysis underpinning DHSC’s proposals. This report summarises the findings from that review.
- Statutory Scheme
Last modified: 29 September 2023
Last reviewed: 29 September 2023